Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Radnostix, Inc. (INIS : OTC)

• Company Description    Radnostix Inc. manufactures a wide range of radioisotope focused products. The company manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. It also manufactures Cobalt-60 sealed source products. Radnostix Inc., formerly known as International Isotopes Inc., is based in IDAHO FALLS, Idaho. Number of Employees: 45

• Price / Volume Information    Yesterday's Closing Price: $0.05 Daily Weekly Monthly 20 Day Moving Average: 28,132 shares Shares Outstanding: 529.30 (millions) Market Capitalization: $29.11 (millions) Beta: 1.21 52 Week High: $0.11 52 Week Low: $0.05 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -19.12% -18.76% 12 Week -21.43% -23.10% Year To Date -10.28% -20.43%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4137 COMMERCE CIRCLE - IDAHO FALLS,ID 83401 USA ph: 208-524-5300 fax: 208-524-1411 ir@intisoid.com http://www.radnostix.com

• General Corporate Information    Officers Shahe Bagerdjian - Chief Executive Officer and President Christopher Grosso - Chairman W. Matthew Cox - Chief Financial Officer Robert Atcher - Director Steve Laflin - Director Peer Information Radnostix, Inc. (GSAC) Radnostix, Inc. (CASIF) Radnostix, Inc. (ALCD.) Radnostix, Inc. (OMNN) Radnostix, Inc. (CGPI.) Radnostix, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 45972C102 SIC: 3823 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/13/26 Share - Related Items Shares Outstanding: 529.30 Most Recent Split Date: (:1) Beta: 1.21 Market Capitalization: $29.11 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 2.59 EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -26.89% vs. Previous Quarter: 12.32% ROE 06/30/26 - -92.97 03/31/26 - -58.34 12/31/25 - -22.18 ROA 06/30/26 - -16.49 03/31/26 - -12.19 12/31/25 - -5.14 Current Ratio 06/30/26 - 0.84 03/31/26 - 0.88 12/31/25 - 1.16 Quick Ratio 06/30/26 - 0.69 03/31/26 - 0.69 12/31/25 - 0.94 Operating Margin 06/30/26 - -25.52 03/31/26 - -17.56 12/31/25 - -6.95 Net Margin 06/30/26 - -25.52 03/31/26 - -17.56 12/31/25 - -6.95 Pre-Tax Margin 06/30/26 - -25.51 03/31/26 - -17.55 12/31/25 - -6.95 Book Value 06/30/26 - 0.00 03/31/26 - 0.01 12/31/25 - 0.01 Inventory Turnover 06/30/26 - 6.10 03/31/26 - 6.29 12/31/25 - 6.47 Debt-to-Equity 06/30/26 - 1.17 03/31/26 - 0.65 12/31/25 - 0.92 Debt-to-Capital 06/30/26 - 76.86 03/31/26 - 68.62 12/31/25 - 66.86

Powered by Zacks Investment Research ©